Key result
The ACE gene insertion/deletion polymorphism was not significantly associated with migraine risk, nor did it predict clinical response to lisinopril or candesartan prophylaxis.
Why the study?
Does the ACE insertion/deletion polymorphism associate with migraine risk or predict clinical response to lisinopril or candesartan in migraine patients?
Case-Control (n=750)
No
Does the ACE insertion/deletion polymorphism associate with migraine risk or predict clinical response to lisinopril or candesartan in migraine patients?
p-value: p=>0.05
The ACE insertion/deletion polymorphism is not associated with migraine risk or clinical response to lisinopril or candesartan in a Norwegian population.
Does not support ACE I/D testing for migraine risk or prophylaxis prediction; leaves open larger multi-ethnic studies.
BACKGROUND: The main objective of this study was to investigate the angiotensin converting enzyme (ACE) genotype as a possible risk factor for migraine (both with and without aura) compared to controls. We also wanted to examine whether a clinical response to an ACE inhibitor, lisinopril, or an angiotensin II receptor blocker, candesartan, in migraine prophylaxis was related to ACE genotype. METHODS: 347 migraine patients aged 18-68 (155 migraine without aura (MoA), 187 migraine with aura (MwA) and 5 missing aura subgroup data) and 403 healthy non-migrainous controls > 40 years of age were included in the study. A polymerase chain reaction (PCR) was performed on the genomic DNA samples to obtain the ACE insertion (I)/deletion(D) polymorphisms. RESULTS: No significant differences between migraine patients and controls were found with regard to ACE genotype and allele distributions. Furthermore, there was no significant difference between the controls and the MwA or MoA subgroups. CONCLUSION: In our sample there is no association between ACE genotype or allele frequency and migraine. In addition, ACE genotype in our experience did not predict the clinical response to lisinopril or candesartan used as migraine prophylactics.
No takes yet. Share an insight, caveat, or question.
Tronvik et al. (2008) conducted a case-control in Migraine (n=750). ACE gene insertion/deletion (I/D) polymorphism vs. Healthy controls was evaluated on ACE genotype and allele distributions (p=>0.05). The ACE gene insertion/deletion polymorphism was not significantly associated with migraine risk, nor did it predict clinical response to lisinopril or candesartan prophylaxis.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: